Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

This study investigated the efficacy and safety of a gel combining topical calcipotriol and steroid for alopecia areata. It found the combination worked similarly to steroids alone in reducing hair loss, but with fewer side effects.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

In this case study, a neutered British Shorthair cat with diabetes mellitus showed fast remission of facial skin issues using off-label oclacitinib, with no recurrence for 17 months, but required surgery for eyelid cicatrization.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This study found that topical simvastatin induced remission and hair regrowth in a mouse model of alopecia areata, potentially by modulating T cell activity and reducing pro-inflammatory cytokine signaling.

This consensus concluded that oral isotretinoin is highly effective for treating acne and some off-label conditions, with common adverse events being manageable and rare serious risks not contraindicating use.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This case report describes a preterm newborn with lamellar ichthyosis, detailing management with acitretin, vitamin D, and emollients, and emphasizes the importance of regular monitoring due to potential adverse effects of long-term retinoid therapy.

An arthritis drug helped a person with severe hair loss regrow their hair.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study found that a combination of low-fluence Q-switched 1064 nm Nd:YAG laser, hydroquinone cream, and oral tranexamic acid showed promising results for Riehl’s melanosis in Asian patients, with no serious adverse events reported.

This study reports that a combination of upadacitinib and oral minoxidil resulted in complete hair regrowth in a 20-year-old with alopecia universalis, Crohn's disease, and atopic dermatitis.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This paper reviews the diagnosis and treatment of inflammatory tinea capitis, highlighting the importance of laboratory confirmation and recommending griseofulvin as the gold standard treatment.

In this case study, a 46-year-old woman with localized discoid lupus erythematosus on her scalp showed significant improvement with a combination of oral hydroxychloroquine and topical pimecrolimus, despite limited success with previous treatments.

This case report describes a rare instance of prolonged alopecia following acitretin therapy where the patient's hair did not significantly regrow more than six months after stopping treatment.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

In this study, researchers reported that while systemic antibiotics are often chosen first for treating severe folliculitis decalvans, they have a high discontinuation rate, suggesting an urgent need for more effective immunomodulatory treatments.

Tacalcitol ointment effectively improves bilateral nevus comedonicus.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.

This review article highlights the complexity of treating folliculitis decalvans, emphasizing the role of systemic antibiotics like rifampicin and clindamycin as common treatments, while also discussing promising novel therapies, including biological agents, that require further clinical trials to assess their effectiveness and safety.

This report describes common skin CT features of rosacea identified using a reflective confocal microscope, facilitating more objective diagnosis but highlights the need for further clinical exploration.

This case report describes a 37-year-old woman who developed rare acitretin-induced folliculitis after nearly a year of treatment for pustular psoriasis, treated successfully with skin dressing and antibiotics.

This study found that topical Vorinostat induced significant hair regrowth in mice with alopecia areata, suggesting it as a potential repurposable treatment for the condition.